NeuBase Therapeutics Reports Business Update and Financial

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Jessica Yingling ,Toddp Branning ,Dietricha Stephan ,Lifesci Advisors ,Little Dog Communications Inc ,Drug Administration ,Good Laboratory Practice ,Nasdaq ,Huntington Disease Hd Program ,Neubase Therapeutics Inc ,Exchange Commission ,Oncology Program ,Investigational New Drug ,Manufacturing Practice ,Chief Financial Officer ,Base Therapeutics ,Chief Executive Officer ,Chief Financial ,Fiscal Year ,Recent Operating ,Dystrophy Type ,New Chief Financial Officer ,Fiscal Quarter Ended December ,Private Securities Litigation Reform ,Base Investor Contact ,Sci Advisors ,Base Media Contact ,Nasdaq Nbse ,Neubase Therapeutics ,Nc ,